Vancouver, Canada – October 13, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has signed an agreement with a top 10 global pharmaceutical company (“Company”) to jointly test Sirona’s novel skin care, dark spot remover, TFC-1067, in a new clinical study. TFC-1067 will be tested using a new higher concentration (0.4%) and advanced formulation.
The clinical trial, launched October 5th, will run for a period of 12 weeks and include a minimum of 125 participants. It will be managed by Dermscan (a division of Eurofins), a global leader in cosmetic clinical trials. The study’s endpoint is to determine the compound’s ability to reduce hyperpigmentation or “dark spots” of the skin.
Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. The study is expected to complete in early 2021 with results in February 2021. The study protocol was established through a collaboration of the scientific teams of TFChem, Sirona’s wholly owned subsidiary and the Company’s skincare scientific team.
Following the study, the Company will have first access to the clinical study results to assess potential use by its subsidiary dermatology company.
“To have a partner of this magnitude assisting in the design and financing of our clinical trial is a testament to the potential of TFC-1067,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We look forward to continuing our relationship with their clinical team through the study as we evaluate the higher dose and improved formulation of the compound. TFC-1067 has been clinically proven to selectively lighten dark spots and blend them into surrounding skin tone. The ability to lessen visibility of dark spots while preserving underlying skin tone safely is a unique consumer benefit.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
German Investor Relations
Phone: +49 160 920 340 25
Dr. Howard Verrico
CEO, Chairman of the Board
Sirona Biochem Corp.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.